BioXcel Therapeutics에 대한 매도 수량은 투자자에게 BioXcel Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

BioXcel Therapeutics (NASDAQ:BTAI) 주식, 공매도 수량 보고

BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics Inc

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 41.7% to $15.39 during Friday's pre-market session. The company's market cap stands at $33.4 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock rose 34.76% to $0.79. The market value of their outstanding shares is at $6.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock moved upwards by 23.07% to $13.6. The company's market cap stands at $930.4 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares increased by 20.27% to $1.78. The company's market cap stands at $2.2 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 12.58% to $3.4. The market value of their outstanding shares is at $2.9 million. As per the press release, Q3 earnings came out today. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock rose 12.56% to $0.77. The company's market cap stands at $50.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock decreased by 55.0% to $6.08 during Friday's pre-market session. The company's market cap stands at $7.0 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 17.01% to $4.44. The company's market cap stands at $1.5 billion. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares decreased by 14.42% to $0.95. The market value of their outstanding shares is at $107.1 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) shares decreased by 8.87% to $0.52. The company's market cap stands at $22.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 7.93% to $0.29. The company's market cap stands at $4.2 million. </li>
<li>TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) shares declined by 7.88% to $14.75. The market value of their outstanding shares is at $220.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

BTAI

IOBT

LIFW

PROC

REPL

SCNI

SLXN

TBRG

VRPX

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

WIIM

BioXcel Therapeutics shares are trading lower after the company announced a public offering valued at $7 million consisting of shares and warrants.

Including Pre-Funded Warrants For Up To 9M Shares,&nbsp;

News

Offerings

BioXcel Therapeutics Prices $7M Public Offering Of 5.6M Shares And Warrants At $0.48 Per Unit; With Proceeds Supporting Neuroscience And Immuno-Oncology Development Efforts

The Company intends to use the net proceeds of this offering to fund the SERENITY At-Home trial, prepare for the initiation of the TRANQUILITY In-Care trial, working capital and general corporate purposes.
 &nbsp;

BioXcel Therapeutics Commences Public Offering Of Shares Of Its Common Stock And Accompanying Warrants; No Terms Disclosed

BioXcel Therapeutics shares are trading lower after the company reported worse-than-expected Q3 revenue results.

BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.60) by 46.67 percent. This is a 81.4 percent increase over losses of $(1.72) per share from the same period last year. The company reported quarterly sales of $214.00 thousand which missed the analyst consensus estimate of $1.31 million by 83.61 percent. This is a 37.24 percent decrease over sales of $341.00 thousand the same period last year.

Earnings

BioXcel Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.60) Estimate, Sales $214.00K Miss $1.31M Estimate

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.
Analysts estimate that BioXcel Therapeutics will report an earnings per share (EPS) of $-0.52. 
The market awaits BioXcel Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.50, leading to a 5.06% drop in the share price on the subsequent day.
Here's a look at BioXcel Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.71</td>
<td>-0.70</td>
<td>-0.91</td>
<td>-1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.87</td>
<td>-0.76</td>
<td>-1.58</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731510157_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of BioXcel Therapeutics were trading at $0.665 as of November 12. Over the last 52-week period, shares are down 84.48%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BTAI/earnings">To track all earnings releases for BioXcel Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: BioXcel Therapeutics's Earnings Preview

SERENITY At-Home Pivotal Phase 3 trial
<ul>
<li>Designed to evaluate the safety of a 120 mcg dose of BXCL501 in the at-home setting for agitation associated with bipolar disorders or schizophrenia
<ul>
<li>The first patient has been randomized.</li>
<li>The Company&nbsp;announced <a href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-initiation-serenity-home-pivotal">trial initiation</a> on September 5, 2024, with an expected trial duration of 9 to 12 months.</li>
<li>The double-blind, placebo-controlled, 12-week outpatient trial is expected to enroll approximately 200 patients residing at home.</li>
</ul>
</li>
</ul>
TRANQUILITY In-Care Pivotal Phase 3 trial
<ul>
<li>Designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for AAD over a 12-week period
<ul>
<li>Received feedback from the U.S. Food and Drug Administration on proposed protocol</li>
<li>The double-blind, placebo-controlled study trial is expected to enroll a total of approximately 150 patients aged 55 years and older across the spectrum of Alzheimer's disease severity with mild, moderate, and severe dementia with mini-mental state examination (MMSE) scores of 0 to 25 who reside in skilled nursing facilities, memory care units, or assisted living facilities.</li>
<li>The trial is expected to enroll patients with episodic agitation, with patients self-administering 60 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.</li>
<li>The planned primary endpoint is a change from baseline in the Positive and Negative Syndrome Scale-Excitatory Component (PEC) total score at two hours post-first dose. This is the same endpoint used in previous TRANQUILITY trials and in studies that supported the FDA approval of IGALMI&#x2122; (dexmedetomidine) sublingual film.</li>
<li>Continued efficacy evaluations are expected to be conducted through performing additional PEC and complementary efficacy measures, including the global impression of change in agitation.</li>
</ul>
</li>
</ul>

Biotech

Health Care

General

BioXcel Therapeutics Announced The Achievement Of Clinical And Regulatory Progress For Its Pivotal Phase 3 Trials Of BXCLl501 For The Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia (SERENITY At-Home) And Agitation Associated With Alzheimer's Dementia (TRANQUILITY In-Care)

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $7 to $5.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

BioXcel Therapeutics Reports Department Of Defense Grant To University Of North Carolina To Fund Study Of BXCL501; Phase 2a Efficacy And Safety Trial Enrollment Initiation Expected In H1 2025

Bioxcel Therapeutics Will Reduce Its Workforce By 15 Employees, Or Approximately 28% Of The Company's Headcount-Filing

Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $7 Price Target

BioXcel Therapeutics Initiated Patient Enrollment In SERENITY At-home Pivotal Phase 3 Trial Of BXCL501 In At-home Setting For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia. The Trial Duration Currently Is Expected To Be 9 To 12 Months

Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and maintains $7 price target.

Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target

UBS analyst Colin Bristow maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Neutral and lowers the price target from $3.5 to $1.

UBS Maintains Neutral on BioXcel Therapeutics, Lowers Price Target to $1

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) with a Buy and lowers the price target from $10 to $7.

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $7

BioXcel Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

BioXcel Therapeutics Q2 2024 GAAP EPS $(0.21) Beats $(0.77) Estimate, Sales $1.104M Beat $759.200K Estimate

BioXcel Therapeutics Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

BioXcel Therapeutics GAAP EPS of -$0.32 beats by $0.23, revenue of $0.21M misses by $1.12M

Reports Q3 revenue $214,000, consensus $1.33M. "Our focus continues to be the clinical development of BXCL501," said Vimal Mehta, Ph.D., CEO of Bio...

BioXcel Therapeutics reports Q3 EPS (32c), consensus (48c)

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) today. The company's sha...

Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)

BioXcel Therapeutics (BTAI) announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants...

BioXcel announces common stock and warrants offering, no amount given

Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. BioXcel Therapeutics has restructured its credit agreement, introducing new capital-...

Bioxcel Therapeutics Restructures Credit and Strengthens Leadership

BioXcel Therapeutics (BTAI) announced the pricing of an underwritten public offering of 5,600,000 shares of its common stock, par value $0.001 per ...

BioXcel Therapeutics prices 5.6M shares at 48c in public offering

BioXcel Therapeutics announces pricing of $7M public offering

CVSI

DTEGY

EONGY

KEYUF

KNTNF

MKGAF

NLCP

PAVM

POLA

PVCT

QBTS

SACH

SIEGY

SPCB

VEON

VISL

WKHS

XNET

Press Releases

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Financing

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics to Present at ThinkEquity Conference

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

IPOs

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclo Therapeutics

GlycoMimetics

IN8bio

Kairos Pharma

MEI Pharma

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Comments

BioXcel Therapeutics

매도 수량

BioXcel Therapeutics (NASDAQ:BTAI) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌